Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 03, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding director share interests and does not contain financial performance data.
Material Changes
On March 31, 2007, the Company provisionally allocated awards of Ordinary Shares and American Depository Shares (ADSs) to its Non-Executive Directors for the service period of January 1, 2007, to March 31, 2007. The specific allocations were:
- Sir Christopher Gent: 2,071.33 Ordinary Shares
- Dr Stephanie Burns: 133.01 ADSs
- Mr Lawrence Culp: 498.80 ADSs
- Sir Crispin Davis: 1,440.92 Ordinary Shares
- Sir Deryck Maughan: 498.80 ADSs
- Dr Daniel Podolsky: 374.10 ADSs
- Sir Ian Prosser: 990.63 ADSs
- Dr Ronaldo Schmitz: 576.37 ADSs
- Mr Tom de Swaan: 495.32 ADSs
- Sir Robert Wilson: 450.29 ADSs
The Company and the Non-Executive Directors were informed of these allocations on April 2, 2007.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the final vesting terms and conditions attached to the provisional share allocations listed.
- Confirm the total number of shares and ADSs held by each Non-Executive Director post-allocation.
- Review the Company's annual report (Form 20-F) for comprehensive financial performance data not included in this filing.